USANA Health Sciences, Inc. (NYSE:USNA) Director Robert Auciaux Sells 4,018 Shares
USANA Health Sciences, Inc. (NYSE:USNA) Director Robert Auciaux sold 4,018 shares of the firm’s stock in a transaction that occurred on Thursday, September 12th. The shares were sold at an average price of $71.87, for a total transaction of $288,773.66. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.
NYSE USNA traded down $0.27 during mid-day trading on Friday, hitting $71.72. The company’s stock had a trading volume of 141,304 shares, compared to its average volume of 258,496. USANA Health Sciences, Inc. has a 52-week low of $58.30 and a 52-week high of $130.85. The stock’s fifty day simple moving average is $67.62 and its two-hundred day simple moving average is $76.88. The firm has a market capitalization of $1.62 billion, a P/E ratio of 13.90 and a beta of 0.39.
USANA Health Sciences (NYSE:USNA) last posted its quarterly earnings results on Tuesday, July 23rd. The company reported $0.91 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.93 by ($0.02). USANA Health Sciences had a net margin of 9.68% and a return on equity of 27.22%. The business had revenue of $256.00 million during the quarter, compared to analysts’ expectations of $254.66 million. During the same quarter in the previous year, the business posted $1.36 EPS. The company’s quarterly revenue was down 15.1% on a year-over-year basis. As a group, research analysts anticipate that USANA Health Sciences, Inc. will post 3.78 earnings per share for the current year.
USNA has been the topic of several research reports. ValuEngine upgraded shares of USANA Health Sciences from a “sell” rating to a “hold” rating in a report on Thursday, August 1st. Jefferies Financial Group initiated coverage on shares of USANA Health Sciences in a report on Thursday, August 22nd. They issued a “hold” rating and a $65.00 price target on the stock. Pivotal Research restated a “buy” rating on shares of USANA Health Sciences in a report on Wednesday, July 24th. Sidoti lowered shares of USANA Health Sciences from a “buy” rating to a “neutral” rating and set a $70.00 price target on the stock. in a report on Wednesday, July 3rd. Finally, TheStreet lowered shares of USANA Health Sciences from a “b-” rating to a “c+” rating in a report on Thursday, July 11th. Three investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company. The company has a consensus rating of “Hold” and a consensus target price of $70.00.
About USANA Health Sciences
USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional and personal care products primarily to reduce the risk of chronic degenerative disease. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers comprising targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and foods that include low-glycemic meal replacement shakes, snack bars, and other related products, which provide macro-nutrition.
Read More: Do closed-end mutual funds pay dividends?
Receive News & Ratings for USANA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for USANA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.